Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREATH-19: Intravenous tocilizumab for COVID-19 pneumonia
2020-001995-13Phase 2Active
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in coronavirus pneumonia and coronavirus disease 2019 (COVID-19), sponsored by Fundación SEIMC-GeSIDA. Primary endpoint: Primary: Respiratory function. Started May 2020; status: active.
02
Drugs
tocilizumab
03
Conditions
coronavirus pneumoniacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001995-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001995-13.